Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients.

× No keyword cloud information.

23 in total

Review 1. [Severe skin reactions due to new medications].

Authors: M Mockenhaupt; M Paulmann
Journal: Hautarzt Date: 2018-04 Impact factor: 0.751

Review 2. Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy.

Authors: O F Khan; J Monzon
Journal: Curr Oncol Date: 2020-04-01 Impact factor: 3.677

Review 3. Cutaneous Manifestations of Reactions to Biologics.

Authors: Iris M Otani; Amy S Levin; Aleena Banerji
Journal: Curr Allergy Asthma Rep Date: 2018-02-21 Impact factor: 4.806

4. Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors.

Authors: Hajir Ibraheim; Esperanza Perucha; Nick Powell
Journal: Rheumatology (Oxford) Date: 2019-12-01 Impact factor: 7.580

Review 5. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.

Authors: Iosune Baraibar; Ignacio Melero; Mariano Ponz-Sarvise; Eduardo Castanon
Journal: Drug Saf Date: 2019-02 Impact factor: 5.606

Review 6. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors.

Authors: Jennifer Choi; Ronald Anderson; Ada Blidner; Tim Cooksley; Michael Dougan; Ilya Glezerman; Pamela Ginex; Monica Girotra; Dipti Gupta; Douglas Johnson; Vickie R Shannon; Maria Suarez-Almazor; Bernardo L Rapoport; Mario E Lacouture
Journal: Support Care Cancer Date: 2020-08-27 Impact factor: 3.603

Review 7. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.

Authors: Samantha R Ellis; Aren T Vierra; Jillian W Millsop; Mario E Lacouture; Maija Kiuru
Journal: J Am Acad Dermatol Date: 2020-04-29 Impact factor: 11.527

Review 8. Immune checkpoint inhibitor-related dermatologic adverse events.

Authors: Amaris N Geisler; Gregory S Phillips; Dulce M Barrios; Jennifer Wu; Donald Y M Leung; Andrea P Moy; Jeffrey A Kern; Mario E Lacouture
Journal: J Am Acad Dermatol Date: 2020-05-23 Impact factor: 11.527

Review 9. Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.

Authors: Chau Yee Ng; Chun-Bing Chen; Ming-Ying Wu; Jennifer Wu; Chih-Hsun Yang; Rosaline Chung-Yee Hui; Ya-Ching Chang; Chun-Wei Lu
Journal: J Immunol Res Date: 2018-01-17 Impact factor: 4.818

Review 10. Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review).

Authors: Irena Pintea; Carina Petricau; Dinu Dumitrascu; Adriana Muntean; Daniel Constantin Branisteanu; Daciana Elena Branisteanu; Diana Deleanu
Journal: Exp Ther Med Date: 2021-07-03 Impact factor: 2.447